$Hims & Hers Health(HIMS.US) Hims & Hers Health (HIMS.US) announced that it will acquire the Australian digital health service provider Eucalyptus in a cash-and-stock deal valued at up to $1.15 billion. Boosted by the news, the company's shares rose about 7% in pre-market trading on Thursday.

Based in Sydney, Eucalyptus has annual revenue exceeding $450 million and is the largest digital health service provider in Australia. Hims expects this acquisition to help it expand into the Australian and Japanese markets and further grow its business in the UK, Germany, and Canada.

According to the terms of the deal, Hims will need to pay nearly $240 million in cash upon completion. Eucalyptus is also eligible to receive deferred performance-based consideration over the next 18 months and may receive additional payments by early 2029 based on the achievement of financial targets.

Hims can choose to pay most of the deferred and performance-based consideration in cash or stock.

It is understood that Hims, headquartered in San Francisco, California, USA, primarily sells compounded weight-loss drugs. The funding for this transaction is expected to come mainly from the company's existing cash and operating cash flow from its U.S. business. The deal is expected to close in mid-2026.